Transforming growth factor-b (TGF-b) plays complex roles in carcinogenesis, as it may exert both tumor suppressor and pro-oncogenic activities depending on the stage of the tumor. SMAD proteins transduce signals from the TGF-b receptors to regulate the transcription of specific target genes. Crosstalks with other signaling pathways may contribute to the specificity of TGF-b effects. In this report, we have investigated the effects of cyclic adenosine 3 0 ,5 0 -monophosphate (cAMP), a key second messenger in the cellular response to various hormones, on SMAD-dependent signaling in human HaCaT keratinocytes. Using either an artificial SMAD3/4-dependent reporter construct or the natural TGF-b target, plasminogen activator inhibitor-1, we show that membrane-permeable dibutyryl cAMP, and other intracellular cAMP-elevating agents such as the phosphodiesterase inhibitor isobutyl-methylxanthine, the adenylate cyclase activator forskolin, or exogenous prostaglandin E 2 (PGE 2 ), interfere with TGF-b-induced SMAD-specific gene transactivation. Inhibition of protein kinase A (PKA), the main downstream effector of cAMP, with H-89, suppressed cAMP-dependent repression of SMAD-driven gene expression. Inversely, coexpression of either an active PKA catalytic subunit or that of the cAMP response element (CRE)-binding protein (CREB) blocked SMAD-driven gene transactivation. cAMP-elevating agents did not inhibit nuclear translocation and DNA binding of SMAD3/4 complexes, but abolished the interactions of SMAD3 with the transcription coactivators CREB-binding protein (CBP) and p300 in a PKAdependent manner. These results suggest that suppression of TGF-b/SMAD signaling and resulting gene transactivation by cAMP-inducing agents occurs via PKAdependent, CREB-mediated, disruption of SMAD-CBP/ p300 complexes.
Introduction
Cellular signaling from the transforming growth factorb (TGF-b) family of growth factors (e.g. activins, bone morphogenic proteins, and the TGF-b) is initiated by binding of the ligands to transmembrane receptor serine/threonine kinases, TbRI and TbRII. Following receptor activation, signaling from the cell surface to the nucleus occurs predominantly by phosphorylation of cytoplasmic mediators of the SMAD family (Attisano and Wrana, 2000; Massague´and Wotton, 2000) . Briefly, the receptor-associated SMADs (R-SMADs), such as SMAD1, SMAD2, SMAD3, SMAD5, and SMAD8 interact directly with, and are phosphorylated by, activated type I receptors of the TGF-b superfamily. The activation of R-SMADs is ligand specific, but each of them forms, upon phosphorylation, heteromeric complexes with SMAD4 that function as a common mediator for all receptor-activated SMADs. R-SMAD/ SMAD4 complexes are then translocated into the nucleus where they function as transcription factors, directly or in association with other DNA-binding factors. Finally, inhibitory SMADs, such as SMAD6 or SMAD7, interfere with TGF-b signaling by preventing R-SMAD phosphorylation and subsequent nuclear translocation of R-SMAD/SMAD4 complexes, and inducing receptor degradation by recruiting E3 ubiquitin ligases of the Smurf family (Attisano and Wrana, 2000; Massague´and Wotton, 2000) .
One of the first identified second messengers, cyclic adenosine 3 0 ,5 0 -monophosphate (cAMP), transmits signal from a variety of hormones acting at the cell surface via guanine-nucleotide-binding (G)-protein-coupled receptors to activate cAMP-dependent protein kinase A (PKA) (Montminy, 1997) . The balance between adenylate cyclase (AC) and cyclic nucleotide phosphodiesterase activities determines intracellular cAMP levels. In the basal state, PKA resides in the cytoplasm. cAMP induction liberates the catalytic subunits of PKA, which then diffuse into the nucleus where they phosphorylate transcription factors, such as cAMP response elementbinding protein (CREB) (Sassone-Corsi, 1998) . PKA phosphorylates CREB at serine 133, thereby allowing its association with the transcriptional coactivators CBP and p300 (Chrivia et al., 1993; Kwok et al., 1994; Mayr and Montminy, 2001 ). CREB transactivates cAMP-responsive genes by binding as a dimer to a conserved, 8 bp, palindromic cAMP response element (CRE), TGACGTCA. Over 100 genes with functional CREs have been identified thus far (Mayr and Montminy, 2001 ). Interestingly, prostaglandin E 2 (PGE 2 ), a product of the cyclo-oxygenase pathway produced in response to a variety of inflammatory signals, is able to activate AC, and several of the effects of prostaglandins are attributable to elevated cAMP levels and subsequent activation of PKA (Negishi et al., 1993) .
In this study, we have examined the molecular bases for functional interactions between the cAMP/PKA pathway and TGF-b signaling in epithelial cells, using the human immortalized keratinocyte cell line HaCaT (Boukamp et al., 1988) . We provide evidence that cAMP-elevating agents block SMAD3/4-specific transcription in response to TGF-b, as well as plasminogen activator inhibitor-1 (PAI-1) gene expression at the transcriptional level. cAMP neither inhibits SMAD nuclear translocation nor DNA binding of SMAD3/4 signaling complexes to their specific target sequence. On the other hand, elevated cAMP levels interfere with SMAD-driven transcription via PKA-dependent disruption of the association of SMAD proteins with their transcriptional coactivators CBP and p300.
Results cAMP-elevating agents antagonize TGF-b-driven SMAD3/4-dependent gene expression via PKA/CREB activation Several agents known to elevate intracellular cAMP levels were tested for their ability to affect TGF-b-driven transactivation of (CAGA) 9 -lux, an artificial SMAD3/ 4-specific reporter construct consisting of nine repeats of the SMAD3/4-specific recognition sequence, CAGA, cloned upstream of the SV40 minimal promoter and driving the expression of the luciferase gene (Dennler et al., 1998) . As shown in Figure 1a , and as expected from previous observations, TGF-b efficiently transactivated (CAGA) 9 -lux, up to 100-fold above control values. A 30 min preincubation of cultured HaCaT keratinocytes with increasing concentrations of either the membrane-permeable cAMP analog dibutyryl-cyclic AMP (db-cAMP), the phosphodiesterase inhibitor isobutyl-methylxanthine (IBMX), or the AC activator forskolin, resulted in a dose-dependent inhibition of TGF-b-induced SMAD3/4-specific transactivation of (CAGA) 9 -lux. Inhibition of TGF-b-induced SMAD response by cAMP-elevating agents was not restricted to HaCaT keratinocytes, as similar results were obtained in WI-26 human lung fibroblasts and in the human metastatic melanoma cell line 1205Lu (not shown), suggesting that such a suppressive effect of cAMP on TGF-b-induced SMAD signaling is a general phenomenon not dependent on a particular cell type.
We subsequently tried to determine whether the expression of downstream effectors of the cAMP Figure 1 The CAMP-PKA-CREB cascade inhibits TGF-bspecific SMAD-dependent transcription. (a) Subconfluent HaCaT keratinocytes were transfected with (CAGA) 9 -lux in a medium supplemented with 1% FCS. At 3 h after transfection, cAMPelevating agents, db-cAMP, IBMX, and forskolin, were added at the indicated concentrations, without (À) or with ( þ ) TGF-b 10 ng/ml). Incubations were continued for 20 h after which the reporter gene activity was determined. (b) Subconfluent HaCaT keratinocytes were transfected with (CAGA) 9 -lux, together with expression vectors for either the catalytic subunit of PKA or CREB. After 6 h, TGF-b (10 ng/ml) was added ( þ ) and incubations continued for another 20 h before reporter gene activity was determined. (c) HaCaT keratinocytes were transfected with pCRElux in the absence or presence of pPKA expression vector without (À) or with ( þ ) S133-CREB expression vector. Figure 1b , both PKA and CREB overexpression inhibited TGFb-driven transactivation of the SMAD3/4-specific construct (CAGA) 9 -lux. Furthermore, coexpression of PKA and CREB resulted in additive inhibition of (CAGA) 9 -lux induction by TGF-b (Figure 1b) . The CREB effect was dependent on PKA activity, as S133-CREB (Gonzalez and Montminy, 1989 ), a CREB mutant in which the PKA-specific phosphorylation site serine 133 has been substituted to an alanine and exerts a dominant-negative effect against PKA-induced cAMP-dependent transcription (Figure 1c ), did not antagonize TGF-b-induced SMAD3/4-dependent transactivation ( Figure 1d ). The ability of forskolin and db-cAMP to activate cAMP-dependent gene transactivation in HaCaT cells was verified in transient transfections using pCRE-lux. As shown in Figure 2a , forskolin and db-cAMP efficiently transactivated the CRE-dependent construct, 12-16-fold above unstimulated control values. H-89, a specific PKA inhibitor, completely abolished CREdependent response to these cAMP-elevating agents. We next examined the capacity of db-cAMP to induce CREB phosphorylation, and the ability of H-89 to interfere with such a process in HaCaT cells. Results are shown in Figure 2b : exposure of HaCaT keratinocytes to exogenous db-cAMP resulted in the rapid phosphorylation of CREB, which was totally abolished by H-89, consistent with our data obtained on CRE-dependent gene response to cAMP-elevating agents (see above Figure 2a ). Together, these results establish the functionality of the cAMP-PKA-CREB cascade in HaCaT keratinocytes and warrant further investigation of the interference of cAMP-elevating agents with the SMAD pathway in our experimental system.
We have previously shown that the proinflammatory cytokine tumor necrosis factor-a (TNF-a) antagonizes TGF-b/SMAD signaling in a c-Jun-dependent manner (Verrecchia et al., 2000) . To verify the stimulus specificity of PKA in antagonizing TGF-b signaling, HaCaT keratinocytes were transfected with (CAGA) 9 -lux, then treated with either db-cAMP or TNF-a, in the absence or presence of H-89 at 20 mm. This concentration completely inhibits cAMP-induced, PKA-dependent, CREB phosphorylation (see Figure 2b ). As shown in Figure scription (À45 vs À47%), whereas it completely prevented the inhibitory activity of db-cAMP (À11 vs À66%). The enhancement of TGF-b response by H-89 is likely representative of an inhibitory effect of basal PKA activity against TGF-b/SMAD signaling, derepressed by H-89. Of note, a similar potentiation of TGF-b-driven SMAD-specific transactivation was observed when HaCaT cells were pretreated with 2 0 ,5 0 -dideoxyadenosine, a potent inhibitor of AC (data not shown). Together, these results indicate that basal AC and PKA activities play a negative regulatory role against TGF-b-induced SMAD signaling. On the other hand, it appears that PKA is not involved in the antagonistic activity exerted by TNF-a against SMAD signaling, consistent with our data identifying AP-1 as a critical component of TNF-a inhibitory effect (Verrecchia et al., 2000) , requiring functional Jun-N-terminal kinase (JNK) activity (Verrecchia et al., 2003) .
cAMP does not affect SMAD nuclear translocation and the capacity to form complexes with DNA in response to TGF-b Several approaches were taken to gain an insight into the molecular mechanisms underlying the inhibitory activity of the cAMP pathway against SMAD3/4 signaling. First, we examined whether db-cAMP was able to interfere with the translocation of SMAD proteins induced by TGF-b. To this aim, HaCaT keratinocytes were pretreated or not with db-cAMP before TGF-b was added for 30 min. An antibody directed against SMAD2 and SMAD3, the specific R-SMAD substrates for activated TbRI, was used to determine their cellular localization (Figure 3a ). Slides were counterstained with DAPI to localize cell nuclei precisely (right panels). As shown in the upper left panel, a weak and diffuse signal specific for SMAD2/3 was present in both the cytoplasm and nuclei from unstimulated HaCaT cells. TGF-b induced a rapid and complete nuclear translocation of all SMAD2/3-specific immunoreactivity (middle left panel), which was not affected by a 30 min preincubation with db-cAMP (lower left panel), otherwise sufficient to interfere with SMAD-dependent transcription (see Figure 1) .
We next tried to determine whether cAMP may interfere with SMAD-DNA complex formation.
HaCaT keratinocytes were incubated with TGF-b for 30 min, an incubation time shown to be optimal for maximal SMAD-DNA complex formation and detection (Vindevoghel et al., 1998) , without or with SMAD3/4-DNA complexes were detected in electrophoretic mobility shift assay (EMSA) experiments using a radiolabeled 3 Â CAGA probe (Dennler et al., 1998) . As shown in Figure 3b (upper panel), consistent with previous observations (Vindevoghel et al., 1998; Verrecchia et al., 2000) , a 30 min incubation of HaCaT cells with TGF-b resulted in the formation of a unique protein-DNA complex (lane 2) that was supershifted with an anti-SMAD3 antibody (lower panel), attesting for its identity as a TGF-b-specific SMAD-DNA complex. Preincubation of the cells with db-cAMP for 2, 5, and 10 min prior to TGF-b addition had no effect on SMAD-DNA complex formation (Figure 3b , upper panel, lanes 4, 6, and 8 vs lane 2). From these experiments, we conclude that elevated cAMP levels do not affect the nuclear translocation of SMADs in response to TGF-b, nor do they affect the formation of SMAD-DNA complexes.
CBP/p300 squelching by activated CREB is central to the interference of the cAMP cascade with SMAD signaling
Another possibility by which the cAMP pathway may interfere with SMAD-dependent transcription is at the level of recruitment of transcriptional coactivators. The role for CBP and p300 as essential coactivators for SMAD-driven gene expression has been well documented (Feng et al., 1998; Janknecht et al., 1998; Pouponnot et al., 1998; Shen et al., 1998; Topper et al., 1998) . Competition for CBP/p300 has also been suggested to mediate some examples of signal-induced transcriptional repression. Indeed, in the context of SMAD signaling, CBP/p300 squelching by c-Jun or Stat1 may explain, at least in part, the antagonism exerted by TNF-a and interferon-g against SMAD signaling (Verrecchia et al., 2000; Ghosh et al., 2001) . As a first approach to determine whether the cAMP pathway could interfere with SMAD3-CBP or SMAD3-p300 interactions, we used a method based on the mammalian two-hybrid system. In a first set of experiments, HaCaT keratinocytes were transfected with a Gal4-lux reporter construct together with a Gal4 DNA-binding domain-SMAD3 fusion protein (Gal4-SMAD3) expression vector, in the absence or presence of a VP16 activation domain-CBP (VP-CBP) fusion expression vector. As shown in Figure 4a , Gal4-SMAD3 transactivated Gal4-lux in the presence of TGF-b, representative of the transactivation property of phosphorylated SMAD3. Coexpression of VP-CBP together with Gal4-SMAD3 strongly enhanced luciferase activity, representative of SMAD3-CBP interaction. Figure 4 db-cAMP prevents SMAD3-CBP and SMAD3-p300 interactions in a mammalian two-hybrid assay. (a) Subconfluent HaCaT keratinocyte cultures were transfected with Gal4-lux and Gal4-SMAD3, without (À) or with ( þ ) VP-CBP. After 6 h, TGF-b (10 ng/ml) was added where indicated, following ( þ ) or not (À) by a 30 min preincubation with db-cAMP (1 mm). Gal4-lux activity was determined 20 h later. (b) Subconfluent HaCaT keratinocyte cultures were transfected with Gal4-lux and Gal4-p300, without (À) or with ( þ ) VP-SMAD3. After 6 h later, TGF-b (10 ng/ml) was added where indicated, following ( þ ) or not (À) a 30 min preincubation with dbcAMP (1 mm). Gal4-lux activity was determined 20 h later. (c) Subconfluent HaCaT keratinocytes were transfected with (CAGA) 9 -lux, together with either empty pRSVe or p300 expression vector. After 6 h, db-cAMP (1 mm) was added and incubations continued for another 20 h in the absence (À) or presence ( þ ) of TGF-b (10 ng/ml) before reporter gene activity was determined. Results from representative experiments performed with duplicate samples are shown c
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The latter was efficiently abolished by exogenously added db-cAMP, as well as by forskolin (not shown). In another set of experiments, HaCaT keratinocytes were transfected with a Gal4-lux reporter construct together with a Gal4-p300 expression vector, in the absence or presence of a VP-SMAD3 fusion expression vector. Similar to the data described above on the association of SMAD3 with CBP, SMAD3-p300 interactions were also abolished by exogenous db-cAMP (Figure 4b) , suggesting that activation of the PKA pathway affects the association of SMAD3 with both transcriptional coactivators CBP and p300.
As the amount of p300 is limiting within the cell nucleus (Hottiger et al., 1998) , the formation of CREBp300 complexes may reduce the amount of p300 available to Smad3 for optimal transcription. If this scenario is correct, then, overexpression of p300 should overcome the inhibitory effect of cAMP on TGF-b/ SMAD3 activation of the (CAGA) 9 -lux construct. To test this hypothesis, we measured the effect of p300 overexpression on db-cAMP inhibition of (CAGA) 9 -lux transactivation by TGF-b. As shown in Figure 4c , p300 overexpression prevented the inhibitory effect of dbcAMP. It should also be noted that p300 overexpression resulted in increased (CAGA) 9 -lux activity in response to TGF-b stimulation, a result that is consistent with the concept of limited availability of p300, and confirms the role of p300 as a SMAD3 coactivator (Feng et al., 1998; Janknecht et al., 1998; Pouponnot et al., 1998; Shen et al., 1998; Topper et al., 1998) .
From the data presented above, it appears that elevation of intracellular cAMP directly affects the interaction of SMAD3 with its transcriptional coactivators CBP and p300. This effect is probably due to p300/CBP squelching from SMAD complexes by CREB, resulting in the blockade of SMAD-specific transcription.
cAMP-elevating agents interfere with TGF-b-induced, SMAD-dependent, PAI-1 gene expression
The data presented above and obtained using artificial, pathway-specific reporter constructs led us to examine whether cAMP-elevating agents interfere with the activation of a natural, prototypic TGF-b/SMAD target. As a first approach to test this hypothesis, HaCaT cells were transfected with p800-lux, which consists of 800 bp of the human PAI-1 promoter driving the expression of the luciferase gene (Keeton et al., 1991) . As shown in Figure 5a , db-cAMP dose-dependently inhibited TGF-b-driven p800-lux transactivation. Figure 5 The cAMP-PKA-CREB cascade inhibits TGF-b-induced PAI-1 gene expression. (a) Subconfluent HaCaT keratinocytes were transfected with the PAI-1 promoter/reporter gene construct p800-lux in a medium supplemented with 1% FCS. At 3 h after transfection, cAMP-elevating agents, db-cAMP, IBMX, and forskolin, were added at the indicated concentrations, without (À) or with ( þ ) TGF-b 10 ng/ ml). Incubations were continued for 20 h after which the reporter gene activity was determined. (b) Subconfluent HaCaT keratinocytes were transfected with p800-lux. At 3 h after transfection, cells were treated ( þ ) or not (À) with H-89. After 1 h, db-cAMP was added, without (À) or with ( þ ) TGF-b10 ng/ml) (c) Subconfluent HaCaT keratinocytes were transfected with p800-lux, together with empty RSVe or PKA expression vector. After 6 h, TGF-b (10 ng/ml) was added ( þ ) and incubations continued for another 20 h before the reporter gene activity was determined. In addition, both forskolin and IBMX efficiently antagonized TGF-b effect. Such antagonism of dbcAMP against TGF-b-driven p800-lux transactivation was blocked by the PKA inhibitor H-89 (Figure 5b ). In another set of experiments, p800-lux was cotransfected with an expression vector for the catalytic subunit of PKA. As shown in Figure 5c , TGF-b-driven PAI-1 promoter transactivation was blocked by overexpression of PKA. Together, these results demonstrate efficient transcriptional repression of TGF-b-induced PAI-1 promoter transactivation by cAMP-elevating agents in a PKA-dependent manner, similar to what is observed when using the SMAD3/4-specific (CAGA) 9 -lux reporter construct.
To determine whether the regulation of endogenous PAI-1 followed the same regulatory pattern as p800-lux, HaCaT keratinocytes were incubated for 24-48 h with TGF-b in the absence or presence of either db-cAMP or forskolin. PAI-1 production was then assessed by Western blotting. As shown in Figure 5d (upper panel), TGF-b strongly elevated PAI-1 production by keratinocytes, but this effect was efficiently blocked by both db-cAMP and forskolin. In the mean time, actin levels were not altered by any of the treatments. Quantitative analysis of the blots with a phosphorimager revealed that db-cAMP and forskolin inhibited TGF-b effect by 70-80%.
PGE 2 represses TGF-b-induced SMAD-dependent gene transcription in a PKA-dependent manner
To validate our findings in the context of a natural cAMP-elevating agent, we examined the effects of exogenous PGE 2 on TGF-b-dependent SMAD-specific transcription and PAI-1 gene regulation. In a first set of experiments, we first verified the ability of PGE 2 to activate CREB-dependent transcription, representative of the activation of the cAMP signaling cascade. HaCaT keratinocytes were transfected with pCRE-lux. As shown in Figure 6a , efficient transactivation of pCRElux was observed in response to exogenous PGE 2 , which could be totally prevented by the PKA inhibitor H-89. Next, HaCaT keratinocytes were transfected with (CAGA) 9 -lux. As shown in Figure 6b , PGE 2 antagonized TGF-b-driven SMAD3/4-dependent transactivation. In another series of experiments, HaCaT cells transfected with the PAI-1 promoter/reporter construct p800-lux. Similar to the effect observed on (CAGA) 9 -lux, PGE 2 antagonized TGF-b-induced PAI-1 promoter activity, an effect that was abolished by H-89 (Figure 6c ). Taken together, these results indicate that a PKAdependent mechanism mediates PGE 2 action against TGF-b-driven SMAD3/4 signaling and resulting PAI-1 transactivation.
Discussion
Our results provide definitive evidence that cAMPelevating agents interfere with TGF-b-specific SMAD3/ 4-dependent gene expression in a PKA-dependent manner. Such interference with SMAD-dependent transcription occurs in the nucleus via reduction of SMAD3-CBP/p300 interactions and possible sequestration of the transcriptional coactivators CBP and p300 by phosphorylated CREB, whereas SMAD translocation in response to TGF-b is not affected. Likewise, the ability of SMAD proteins to bind DNA in vitro is not affected by cAMP-inducing agents. Such a mechanistic model applies to the regulation of PAI-1, a natural TGFb/SMAD target. It also provides a molecular explanation for the inhibitory effect of cAMP-elevating agents, membrane-permeable 8-Br-cAMP and the AC activator cholera toxin, against TGF-b-induced connective tissue growth factor (CTGF) gene expression and collagen (Duncan et al., 1999) , since the CTGF, PAI-1 and fibrillar collagen genes are direct SMAD targets (Dennler et al., 1998; Leask et al., 2001; Verrecchia et al., 2001a) .
Escape of epithelial cells from TGF-b growth control is a hallmark of many cancers. The presence of inactivating mutations in genes encoding TGF-b receptors and SMADs in human carcinomas and various studies of tumor development in mouse models underscore the role of TGF-b signaling as a tumor suppressor pathway controlling epithelial cell growth and maintaining genetic stability in early carcinogenesis (Gold, 1999; Reiss, 1999; de Caestecker et al., 2000) . Inversely, TGF-b may become pro-oncogenic at later stages of carcinogenesis, and high levels of TGF-b expression correlate with the advanced clinical stage of a tumor. Tumor-derived TGF-b exacerbates the malignant phenotype of transformed and tumor-derived cells, and may contribute to tumor growth indirectly by suppressing immunosurveillance, stimulating the production of proangiogenic factors, or facilitating invasion and metastasis (Gold, 1999; Reiss, 1999; de Caestecker et al., 2000) . It is expected that deciphering the complex crosstalks between the SMAD cascade and other signaling pathways will lead to a better understanding of the bifunctional tumor suppressor/oncogenic role of TGF-b that depends on the state of tumorigenesis. It may be interpreted that chemoprevention is likely to require mechanisms that potentiate TGF-b/SMAD signaling, whereas, on the other hand, late-stage carcinogenesis will require approaches that either inhibit TGF-b signals to allow immune rejection of tumors, or restore TGF-b growth control in tumor cells.
A growing body of evidence indicates that cyclooxygenase, hence prostaglandin synthesis, is involved in carcinogenesis, inducing the production of angiogenic factors and enabling resistance to apoptosis of cancer cells (Sheng et al., 1998; Tsujii et al., 1998) . PGE 2 , which stimulates the growth of both normal colon and colon cancer cells (Sheng et al., 2001) , exhibits elevated levels in colorectal cancer (Levy, 1997) . Conversely, cyclooxygenase inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to exert antineoplastic effects, and to decrease the risk of colorectal, breast, or esophagal carcinomas (Smalley et al., 1999; Johnson et al., 2002; Corley et al., 2003) . Similarly, PKA inhibitors may also be considered as therapeutic agents for cancer therapy, as it has been shown that combined blockade of PKA and EGF receptor activities exerts a synergistic antitumor effect in a variety of experimental models both in vitro and in vivo (Tortora and Ciardiello, 2002) . Moreover, PKA inhibitors cooperate with cytotoxic drugs and ionizing radiations to inhibit tumor growth and angiogenesis (Tortora et al., 1997; Bianco et al., 2000) .
In the present report, we have shown that agents that activate PKA, for example PGE 2 and cAMP analogs, are able to antagonize SMAD signaling. These results provide a mechanistic explanation for some of the observed effects of NSAIDs and PKA inhibitors in the context of chemoprevention and cancer treatment, as these drugs, through the modulation of PKA activity, may directly interfere with SMAD signaling initiated by TGF-b, a complex gatekeeper in carcinogenesis (Gold, 1999; Reiss, 1999; de Caestecker et al., 2000) .
Materials and methods

Cell culture and biochemical reagents
The human epidermal HaCaT keratinocyte and human lung WI-26 fibroblast cell lines were maintained in Dulbecco's modified Eagle's medium supplemented with 10% heatinactivated fetal calf serum (FCS), 2 mm glutamine, and antibiotics (100 U/ml penicillin, 50 mg/ml streptomycin-G and 0.25 mg/ml Fungizone t ) in a humidified atmosphere of 5% CO 2 . The human melanoma cell line 1205-Lu, a kind gift from Dr M Herlin (Wistar Institute, Philadelphia, PA, USA), shown previously to have functional, even exacerbated, SMAD signaling (Rodeck et al., 1999) , was grown in a composite medium (W489) consisting of three parts MCDB153 and one part L15 supplemented with 4% FCS. Human recombinant TGF-b1, as well as recombinant human TNF-a, was purchased from R&D Systems Inc. (Minneapolis, MN, USA). It is referred to as TGF-b throughout the text. PGE 2 , forskolin, 3-isobutyl-1-methylxanthine (IBMX), dibutyryl-cAMP (db-cAMP), and the PKA inhibitor H-89 were purchased from Sigma Chemical Co., Saint-Louis, MO, USA.
Immunofluorescence
Cells seeded into eight-well tissue chambers (Lab-Tek, Nalge Nunc Int, Naperville, IL, USA) were fixed and permeated with 3% paraformaldehyde for 15 min, followed by Tween 0.5% for additional 30 min. Nonspecific binding was blocked with BSA 0.1%. Endogenous SMAD2/3 content was visualized by incubation for 1 h at room temperature with a monoclonal anti-SMAD2/3 antibody (1 : 200, Transduction Laboratories, Lexington, KY, USA). After washing, bound antibodies were visualized by secondary sheep anti-mouse IgG antibodies conjugated with Cy3 (1 : 250, Sigma). After three final washes, slides were counterstained with DAPI to visualize cell nuclei, mounted in Vectashield t (Vecta Laboratories, Burlingame, CA, USA) and stored at þ 41C protected from light until use. For negative controls, whole mouse serum was used instead of the primary antibody or, the primary antibody was omitted. Cells were imaged with a confocal laser scanning microscope (BioRad Cell Science Division, Hemel Hempstead, UK).
Plasmid constructs
(CAGA) 9 -lux, a gift from Drs S Dennler and J-M Gauthier (Glaxo-Welcome, Les Ulis, France), an SMAD3/4-specific reporter has been described previously (Dennler et al., 1998) . p800-Lux, which contains 800 bp of human PAI-1 promoter linked to the luciferase gene, was a kind gift of Dr DJ Loskutoff (Research Institute of Scripps Clinic, La Jolla, CA, USA) (Keeton et al., 1991) . pCRE-lux (Mercuryt pathway luciferase system, Clontech, Palo Alto, CA, USA) was used to determine CRE-driven transcription. The Gal4-luciferase plasmid G5E1b-Luc (Gal4-lux) containing five Gal4-binding sites driving the expression of luciferase and the Gal4-SMAD3 fusion protein expression vector have been described previously (Atfi et al., 1997) . Additional expression vectors used in this study were: Gal4-p300 (a kind gift from Dr A Giordano, Thomas Jefferson University, Philadelphia, PA, USA) (Yuan et al., 1996) , Gal4-CREB, VP-CBP, the catalytic figure legends) . Following incubation, cells were rinsed twice with phosphate-buffered saline, harvested by scraping and lysed in 100 ml of reporter lysis buffer (Promega Corp., Madison, WI, USA). Aliquots corresponding to identical protein amounts were used for each reporter assay. Luciferase activity was determined with a commercial assay kit according to the manufacturer's protocol (Promega).
Electrophoresis mobility shift assays
A 39 bp SMAD3/4-specific probe, 3 Â CAGA (Dennler et al., 1998) , was used to determine the effect of forskolin and dbcAMP on TGF-b-induced SMAD3/4-DNA complex formation. Nuclear extracts were isolated using a small-scale preparation (Andrews and Faller, 1991) , aliquoted into small fractions to avoid repetitive freeze-thawing, and stored at À801C until use. The protein concentration in the extracts was determined using a commercial assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Binding mixtures were separated electrophoretically on 4% acrylamide gels in 0.5% TrisBorate-EDTA as described previously (Verrecchia et al., 2001b) .
Western blotting
Subconfluent HaCaT cells were placed in a fresh medium containing 1% FCS for 24 h before stimulation with various cAMP-elevating agents. The cells were washed with cold PBS and lysed by the addition of an SDS lysis buffer (100 mm Tris-HCl (pH 6.8), 1% SDS, 0.1 m dithiothreitol, 0.1 mm orthovanadate) followed by boiling for 5 min. Proteins (50 mg/lane) were separated on 10% or 12% SDS-polyacrylamide gels and transferred to nitrocellulose Hybond ECL þ (Amersham Pharmacia Biotech, Uppsala, Sweden). After blocking with 5% nonfat dry milk in 20 mm Tris (pH 7.6), 137 mm NaCl, and 0.1% Tween-20 for 1 h at room temperature, filters were incubated with either anti-CREB (1 : 2000 dilution), anti-phospho-CREB (1 : 1000 dilution) (both from New England Biolabs, Beverly, MA, USA), monoclonal C9 anti-PAI-1 (1 : 200 dilution, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), or anti-actin (Sigma Co., 1 : 5000 dilution) antibodies in blocking solution overnight at 41C. After three washes in 20 mm Tris (pH 7.6), 137 mm NaCl, 0.1% Tween-20, membranes were incubated with species-specific (anti-rabbit or anti-mouse) IgG-horseradish peroxidase-conjugated antibodies (1 : 5000 dilution) (Santa Cruz Biotechnology Inc.) in blocking solution for 1 h at room temperature. Membranes were then washed three times with wash buffer (see above), and detection of immunoreactive proteins was performed with the ECL þ Plus chemiluminescent reagent according to the manufacturer's instructions (Amersham Pharmacia Biotech) using a phosphorimager (Storm 840, Amersham Pharmacia Biotech).
Abbreviations AC, adenylate cyclase; CBP, CREB-binding protein; CRE, cAMP Response element; CREB, CRE-binding protein; db-cAMP, dibutyryl-cyclic AMP; EMSA, electrophoretic mobility shift assay; FCS, fetal calf serum; IBMX, isobutylmethylxanthine; PAI-1, plasminogen activator inhibitor-1; PGE 2 , prostaglandin E 2 ; PKA, protein kinase A; TGF-b, transforming growth factor-b; TNF-a, tumor necrosis factor-a .
